Your session is about to expire
← Back to Search
Proteasome Inhibitor
DKRd Regimen for Multiple Myeloma
Phase 2
Waitlist Available
Led By Andrzej Jakubowiak, MD, PhD
Research Sponsored by University of Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Woman of childbearing potential must have 2 negative pregnancy tests prior to initiating lenalidomide
Diagnosis of symptomatic multiple myeloma as per current International Myeloma Working Group (IMWG) uniform criteria prior to initial treatment
Must not have
Myocardial infarction within 6 months prior to enrollment, New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
Known or suspected chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) <50% of predicted normal
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
All Individual Drugs Already Approved
Approved for 60 Other Conditions
No Placebo-Only Group
Summary
This trial is testing a new cancer treatment regimen for multiple myeloma.
Who is the study for?
This trial is for adults with newly diagnosed, untreated multiple myeloma who need systemic chemotherapy. They must have measurable disease, good performance status (able to carry out daily activities), and proper liver function. Women of childbearing age must use two forms of contraception or abstain from sex, and men must use condoms. Participants cannot join if they have certain heart conditions, severe lung problems like COPD or asthma, recent major surgery, active infections requiring treatment within the last two weeks, or a history of other cancers in the past three years.
What is being tested?
The study tests a combination therapy called D-KRd: daratumumab (an antibody that targets cancer cells), carfilzomib (a drug that disrupts cancer cell waste disposal), lenalidomide (which affects the immune system and can kill cancer cells) and low dose dexamethasone (a steroid to reduce inflammation). The response rate after eight cycles will be measured to see how well this regimen works against multiple myeloma.
What are the potential side effects?
Possible side effects include reactions at the infusion site for daratumumab; heart issues and shortness of breath from carfilzomib; blood clots, fatigue, diarrhea from lenalidomide; and increased blood sugar levels due to dexamethasone. There may also be an increased risk of infection due to effects on white blood cells.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am a woman who can have children and have had 2 negative pregnancy tests before starting lenalidomide.
Select...
I have been diagnosed with symptomatic multiple myeloma.
Select...
My bone marrow has more than 10% plasma cells or I have a confirmed plasmacytoma.
Select...
My kidney function is good, with a creatinine clearance rate of at least 50 mL/min or my serum creatinine is below 2 g/dL.
Select...
I have newly diagnosed myeloma and need chemotherapy.
Select...
I am fully active or have some restrictions but can still care for myself.
Select...
My liver tests are within the normal range.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I haven't had a heart attack in the last 6 months and don't have severe heart issues.
Select...
I have COPD with less than half the normal lung function.
Select...
My blood pressure or diabetes is not well-managed.
Select...
I have not taken antibiotics, antivirals, or antifungals for an infection in the last two weeks.
Select...
My multiple myeloma does not show up in standard blood or urine tests.
Select...
I have POEMS syndrome.
Select...
I have been diagnosed with amyloidosis.
Select...
I have been diagnosed with plasma cell leukemia.
Select...
I have Waldenström's macroglobulinemia or IgM myeloma.
Select...
I haven't been in a drug study within the last 3 weeks or 5 drug half-lives.
Select...
I have moderate to severe numbness, tingling, or pain in my hands or feet.
Select...
I have mild to no diarrhea without taking medication for it.
Select...
My cancer has spread to my brain or spinal cord.
Select...
I cannot tolerate daratumumab, carfilzomib, lenalidomide, or dexamethasone.
Select...
I have had a blood clot in my lung.
Select...
I have been diagnosed with moderate or severe asthma or COPD.
Select...
I have not had major surgery in the last 3 weeks.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 60 Other Conditions
This treatment demonstrated efficacy for 60 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Treatment Arm (D-KRd)Experimental Treatment4 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Carfilzomib
FDA approved
Dexamethasone
FDA approved
Daratumumab
FDA approved
Lenalidomide
FDA approved
Find a Location
Who is running the clinical trial?
University of ChicagoLead Sponsor
1,056 Previous Clinical Trials
760,834 Total Patients Enrolled
19 Trials studying Multiple Myeloma
2,395 Patients Enrolled for Multiple Myeloma
Janssen Scientific Affairs, LLCIndustry Sponsor
164 Previous Clinical Trials
579,898 Total Patients Enrolled
24 Trials studying Multiple Myeloma
1,995 Patients Enrolled for Multiple Myeloma
AmgenIndustry Sponsor
1,434 Previous Clinical Trials
1,395,761 Total Patients Enrolled
97 Trials studying Multiple Myeloma
20,690 Patients Enrolled for Multiple Myeloma
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have a high level of protein in your urine.I will provide a bone marrow sample for the study.I am 18 years old or older.I am a woman who can have children and have had 2 negative pregnancy tests before starting lenalidomide.I haven't had a heart attack in the last 6 months and don't have severe heart issues.I have COPD with less than half the normal lung function.I have been diagnosed with plasma cell leukemia.I have Waldenström's macroglobulinemia or IgM myeloma.I haven't been in a drug study within the last 3 weeks or 5 drug half-lives.I have moderate to severe numbness, tingling, or pain in my hands or feet.I do not have an active HIV, HBV, or HCV infection, or I am only HBV positive due to vaccination.I haven't had cancer in the last 3 years, except for certain low-risk types or those considered cured by surgery.I have been diagnosed with symptomatic multiple myeloma.I agree to use a condom during the study and for 90 days after, even if I've had a vasectomy.My kidney function is good, with a creatinine clearance rate of at least 50 mL/min or my serum creatinine is below 2 g/dL.My blood pressure or diabetes is not well-managed.I have mild to no diarrhea without taking medication for it.My cancer has spread to my brain or spinal cord.I have not taken antibiotics, antivirals, or antifungals for an infection in the last two weeks.You have measurable levels of a specific protein in your blood according to current guidelines.My multiple myeloma does not show up in standard blood or urine tests.I have POEMS syndrome.I have been diagnosed with amyloidosis.My bone marrow has more than 10% plasma cells or I have a confirmed plasmacytoma.I've had treatments for myeloma complications but not beyond the specified limits.I cannot tolerate daratumumab, carfilzomib, lenalidomide, or dexamethasone.Your white blood cell count, red blood cell count, and platelet count are within certain healthy ranges.I have had moderate to severe asthma in the last 2 years or currently have uncontrolled asthma.Your heart's electrical activity (QT interval) is too long on a special heart test (ECG).I have newly diagnosed myeloma and need chemotherapy.I haven't had widespread radiotherapy or immunotherapy in the last 4 weeks.You have a detectable disease that can be measured before starting treatment.If the blood test for M-protein is not reliable, then we can use quantitative immunoglobulin levels instead.I agree to use two forms of birth control or abstain from sex while in the study.I have had a blood clot in my lung.I have been diagnosed with moderate or severe asthma or COPD.People who are frail and not eligible for organ transplants, as defined in a specific medical publication by Palumbo et al in 2015.You have signs that your disease is getting worse according to specific medical criteria.I am fully active or have some restrictions but can still care for myself.My liver tests are within the normal range.I have not had major surgery in the last 3 weeks.You have a high level of M-protein in your blood.
Research Study Groups:
This trial has the following groups:- Group 1: Treatment Arm (D-KRd)
Awards:
This trial has 3 awards, including:- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 60 Other Conditions - This treatment demonstrated efficacy for 60 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger